Related Experiment Video

Updated: Jul 10, 2026

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

Pediatric acute myeloid leukemia: towards high-quality cure of all patients

Gertjan J L Kaspers1, Christian M Zwaan

  • 1Pediatric Oncology/Hematology, VU University Medical Center, De Boelelaan 1117 NL-1081 HV Amsterdam, The Netherlands. gjl.kaspers@vumc.nl

Haematologica
|November 21, 2007
PubMed

Insights

Childhood acute myeloid leukemia (AML) survival has improved, but intensive treatments cause side effects. Future therapies aim for better cure rates with targeted treatments for pediatric AML.

Area of Science:

  • Pediatric Hematology/Oncology
  • Cancer Genomics and Targeted Therapy

Background:

  • Childhood acute myeloid leukemia (AML) prognosis has improved, with cure rates reaching approximately 60%.
  • Current intensive chemotherapy regimens for pediatric AML lead to significant treatment-related mortality and long-term side effects.

Purpose of the Study:

  • To review current and future classifications of pediatric AML.
  • To discuss ongoing clinical trials and subgroup-directed treatment strategies.
  • To explore novel therapeutic opportunities for improving cure rates in pediatric AML.

Main Methods:

  • Review of current literature on pediatric AML classification and treatment.
  • Discussion of risk-group stratification methods, including minimal residual disease monitoring, pharmacogenomics, and molecular abnormalities.
  • Exploration of innovative therapies such as novel drug analogues, monoclonal antibodies, and tyrosine kinase inhibitors.

Main Results:

  • Significant advancements in understanding pediatric AML biology.
  • Development of new targeted drugs and therapeutic strategies.
  • Potential for improved risk stratification to enable personalized treatment approaches.

Conclusions:

  • Further refinement of pediatric AML treatment is needed to reduce toxicity.
  • Precision medicine approaches, including targeted therapies, hold promise for improving outcomes.
  • The goal is to achieve high-quality cure for nearly all children and adolescents with AML in the coming decades.

More Related Videos

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...